drugset / Trial / NCT01861340
Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma
Phase 0
Completed
20 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
MedImmune LLC · collab
NaSingle-groupOpen-labelBasic science
Summary
This research study is being done to see if combining the investigational chemotherapy drug, MEDI-551 with the known anti-myeloma drugs, Lenalidomide and Dexamethasone will reduce your myeloma cancer stem cells.
Timeline
- Start
- 2014-05
- Primary completion
- 2016-04
- Completion
- 2016-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Inebilizumab | Monoclonal antibody | 4 mg/kg | Intravenous |
| Background | Dexamethasone | Small molecule | — | — |
| Background | Lenalidomide | Other / unclassified | — | — |